Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
95% of Bitcoin Supply Now in Profit as BTC Tops $117K

95% of Bitcoin Supply Now in Profit as BTC Tops $117K

CoinomediaCoinomedia2025/10/08 10:57
By:Ava NakamuraAva Nakamura

Bitcoin breaks $117K, pushing over 95% of its supply into profit, according to Glassnode.On-Chain Metrics Signal Strength in the MarketWhat This Means for Investors

  • Bitcoin crosses $117K for the first time.
  • Over 95% of BTC in circulation is now profitable.
  • On-chain data suggests strong investor sentiment.

Bitcoin ’s bullish momentum has pushed the price above $117,000, and with that surge, over 95% of its circulating supply is now in profit, according to on-chain analytics platform Glassnode. This marks a significant milestone in Bitcoin’s current market cycle and suggests renewed confidence among holders.

The latest price movement means that most Bitcoin holders purchased their BTC at lower prices and are now seeing gains. Historically, such conditions have indicated a robust bull market environment.

On-Chain Metrics Signal Strength in the Market

Glassnode’s data reflects that a vast majority of circulating BTC is now above its cost basis. This kind of on-chain profitability often aligns with growing investor optimism and reduced selling pressure. When holders are in profit, they tend to be less likely to sell their coins, contributing to price stability or even further upward momentum.

In previous bull cycles, similar levels of profitable supply have preceded even higher prices, especially when coupled with growing institutional interest and macroeconomic tailwinds.

📊 UPDATE: Over 95% of Bitcoin's circulating supply has returned to profit with $BTC breaking above $117K, per Glassnode. pic.twitter.com/2WRTq14yl2

— Cointelegraph (@Cointelegraph) October 8, 2025

What This Means for Investors

Crossing the $117K threshold isn’t just a psychological win; it represents a shift in market sentiment. Long-term holders are in profit, traders are re-entering the market, and attention is returning to Bitcoin as a potential hedge and growth asset.

If this trend continues, analysts believe Bitcoin could be poised for even higher levels in the coming months. However, investors are advised to remain cautious, as large price movements can also trigger volatility.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"

Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.

华尔街见闻•2026/09/29 01:01

Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business

Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.

华尔街见闻•2026/09/29 00:51

AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.

华尔街见闻•2026/09/29 00:26